Fresenius Medical Care AG : Significant support
February 01, 2013 at 09:37 am
By
Entry price | Target | Stop-loss | Potential |
---|
€51.93 |
€0 |
€50.6 |
-100% |
---|
According to analysts estimates, the company is trading, on the basis of current prices, 18.26 and 17.5 times the expected results for the next two years. Besides, the enterprise value is worth 2.15 times its sales. These valuation levels theoretically limit the potential for decline, except in case of strong downward revisions of earnings estimates of the company in the coming months.
The share has a bearish configuration below the EUR 52.5 resistance. Nevertheless, the potential drop is limited by the support area located at EUR 51.3 with two moving average (20 and 50-day). This level is tested for several trading sessions and have contained the downward trend, which reinforce their technical significance.
Considering these elements, the timing seems appropriate to buy the share. We will benefit from the support to anticipate a return at EUR 54.35. A stop loss will be set at EUR 50.6.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.